Fig. 2From: Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)Flowchart: 15 patients recruited in the study and allocated to two groups (low-dose group = 3; high-dose group = 8)Back to article page